Estrogen receptor α, but not estrogen receptor β, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-κB ligand) ratio and serum interleukin-6 in male mice

Journal of Endocrinology

Volumn 171, Issue 3, 2001, Pages 425-433

  Lindberg, M K ^a   Erlandsson, M ^a   Alatalo, S L ^a   Windahl, S ^a   Andersson, G ^a   Halleen, J M ^a   Carlsten, H ^a   Gustafsson, J riA ^a   Ohlsson, C ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ESTRADIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ACID PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; FEMALE; FEMUR; GENE EXPRESSION; HORMONE ACTION; MALE; METAPHYSIS; MOUSE; NONHUMAN; ORCHIECTOMY; OVARIECTOMY; PRIORITY JOURNAL; TRABECULAR BONE; VERTEBRA;

ACID PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; CARRIER PROTEINS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GLYCOPROTEINS; INTERLEUKIN-6; ISOENZYMES; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NF-KAPPA B; ORCHIECTOMY; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0035660587     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1710425     Document Type: Article

References (46)

1. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium
2. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
3. Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice
4. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells
5. Preliminary evidence for impaired estrogen receptor-alpha protein expression in osteoblasts and osteocytes from men with idiopathic osteoporosis
6. Localization of estrogen receptor beta protein expression in adult human bone
7. Histopathological and serological progression of experimental Staphylococcus aureus arthritis
8. Effect of testosterone and estradiol in a man with aromatase deficiency
9. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss
10. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1 beta and tumor necrosis factor-alpha: Lack of regulation by 17 beta-estradiol
11. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
12. Evidence of estrogen receptors in normal human osteoblast-like cells
13. Decreased estradiol levels and free androgen index and elevated sex hormone-binding globulin levels in male idiopathic osteoporosis
14. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens
15. Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats
16. Tartrate-resistant acid phosphatase from human bone: Purification and development of an immunoassay
17. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption
18. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
19. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
20. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors
21. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen
22. Generation and reproductive phenotypes of mice lacking estrogen receptor beta
23. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
24. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow
25. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene
26. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
27. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
28. Bone has a sexually dimorphic response to aromatase deficiency
29. Bone histomorphometry: Standardization of nomenclature, symbols, and units
30. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal
31. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
32. Conditioned medium of estrogen-treated osteoblasts inhibits osteoclast maturation and function in vitro
33. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
34. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
35. In vivo analysis of male and female estrogen receptor a, b and double knockouts reveals a dual role for ERb in bone remodelling
36. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens
37. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton
38. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
39. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats
40. Lack of evidence for an increase in interleukin-6 expression in adult murine bone, bone marrow, and marrow stromal cell cultures after ovariectomy
41. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
42. Expression and localization of estrogen receptor-beta in murine and human bone
43. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice
44. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat
45. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice
46. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis